Direct blockade of NLRP3 gene by CRISPR-Cas9 gene editing to reduce glucocorticoid resistance, the indel mutation frequency of the NLRP3 gene increased from 13.6% to 21.4% in the atopic dermatitis mouse model, and the expression levels of inflammatory cytokines IL-1β and IL-18 in skin tissues were significantly reduced. The gene discussed is NLRP3; the disease is atopic eczema.